Real-world evidence (RWE) continues to play a crucial role in the health care industry, with a growing number of stakeholders relying on more robust data sets.
It’s doubly important now for product developers to adapt, and in their post-approval evidence portfolios spotlight the “combined safety, effectiveness and value of their products in real-world patient populations,” according to Delaware-based HealthCore.
Pragmatic trials, studies aimed primarily at keeping decision makers informed, can provide unique answers to address demands of health care payers and policymakers.
These trials help deliver real-world performance and value to bolster reimbursement and pricing, as well as bring more attention to product effectiveness and safety.
